For example, BCR-ABL1 is a well-known fusion oncogene for chronic myeloid leukemia [3], and the TMPRSS2-ERG fusion product leads to over-expression of ERG and helps triggers prostate cancer [4]. This evidence concerns the gene ERG and chronic myelogenous leukemia, BCR-ABL1 positive.